Compile Data Set for Download or QSAR
maximum 50k data
Found 195 with Last Name = 'wise' and Initial = 'm'
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM60917(9-chloranyl-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro...)
Affinity DataKi:  3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025202(9-Aminomethyl-9H-fluorene-2,5,6-triol | CHEMBL5767...)
Affinity DataKi:  43nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50001955((-)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]qu...)
Affinity DataKi:  53nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025206((6,7-Dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)...)
Affinity DataKi:  57nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM55121(3-HYDROXYTYRAMINE HYDROCHLORIDE | 4-(2-aminoethyl)...)
Affinity DataKi:  150nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
TargetD(2) dopamine receptor(BOVINE)
TBA

Curated by ChEMBL
LigandPNGBDBM50001955((-)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]qu...)
Affinity DataKi:  200nMAssay Description:Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(BOVINE)
TBA

Curated by ChEMBL
LigandPNGBDBM50025206((6,7-Dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)...)
Affinity DataKi:  255nMAssay Description:Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025201(9-Aminomethyl-9H-fluorene-3,4-diol | CHEMBL55693)
Affinity DataKi:  380nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025208(6-Chloro-9-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]az...)
Affinity DataKi:  700nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(BOVINE)
TBA

Curated by ChEMBL
LigandPNGBDBM60917(9-chloranyl-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro...)
Affinity DataKi:  790nMAssay Description:Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50004821(2,3,4,5-Tetrahydro-1H-benzo[d]azepine-7,8-diol | C...)
Affinity DataKi:  970nMAssay Description:Compound was tested for binding affinity against dDopamine receptor D1 using [3H]fenoldopam as a radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025204(6-(2-Amino-ethyl)-biphenyl-2,3-diol | CHEMBL299511)
Affinity DataKi:  1.50E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025209(6-Chloro-9-(4-hydroxy-phenyl)-2,3,4,5-tetrahydro-1...)
Affinity DataKi:  1.63E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025207(6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol | CHEMBL57...)
Affinity DataKi:  1.65E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025203(6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol | ...)
Affinity DataKi:  1.74E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025210(6-Phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8...)
Affinity DataKi:  1.79E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(BOVINE)
TBA

Curated by ChEMBL
LigandPNGBDBM50025203(6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol | ...)
Affinity DataKi:  1.80E+3nMAssay Description:Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025205(6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol | CHEM...)
Affinity DataKi:  1.94E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(BOVINE)
TBA

Curated by ChEMBL
LigandPNGBDBM55121(3-HYDROXYTYRAMINE HYDROCHLORIDE | 4-(2-aminoethyl)...)
Affinity DataKi:  2.35E+3nMAssay Description:Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(1A) dopamine receptor(RAT)
TBA

Curated by ChEMBL
LigandPNGBDBM50025211(6-(4-Hydroxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d...)
Affinity DataKi: >3.00E+3nMAssay Description:Displacement of [3H]fenoldopam from Dopamine receptor D1 of rat striatum membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetD(2) dopamine receptor(BOVINE)
TBA

Curated by ChEMBL
LigandPNGBDBM50025202(9-Aminomethyl-9H-fluorene-2,5,6-triol | CHEMBL5767...)
Affinity DataKi:  5.74E+3nMAssay Description:Compound was tested for inhibition of [3H]spiroperidol binding against Dopamine receptor D2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221760(US9314468, Table 7, Compound 47)
Affinity DataIC50:  1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221860(US9314468, Table 7, Compound 147)
Affinity DataIC50:  1nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221834(US9314468, Table 7, Compound 121)
Affinity DataIC50:  4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221796(US9314468, Table 7, Compound 83)
Affinity DataIC50:  4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221857(US9314468, Table 7, Compound 144)
Affinity DataIC50:  4nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221854(US9314468, Table 7, Compound 141)
Affinity DataIC50:  5nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221864(US9314468, Table 8, Compound 2)
Affinity DataIC50:  5.5nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221865(US9314468, Table 8, Compound 3)
Affinity DataIC50:  5.60nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221863(US9314468, Table 8, Compound 1)
Affinity DataIC50:  5.70nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221866(US9314468, Table 8, Compound 4)
Affinity DataIC50:  5.80nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221808(US9314468, Table 7, Compound 95 | US9314468, Table...)
Affinity DataIC50:  7nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221867(US9314468, Table 8, Compound 5)
Affinity DataIC50:  7.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221868(US9314468, Table 8, Compound 6)
Affinity DataIC50:  7.70nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221869(US9314468, Table 8, Compound 7)
Affinity DataIC50:  8.10nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221870(US9314468, Table 8, Compound 8)
Affinity DataIC50:  8.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221793(US9314468, Table 7, Compound 80)
Affinity DataIC50:  9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221853(US9314468, Table 7, Compound 140)
Affinity DataIC50:  9nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221871(US9314468, Table 8, Compound 9 | US9314468, Table ...)
Affinity DataIC50:  9.30nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221872(US9314468, Table 8, Compound 10)
Affinity DataIC50:  9.90nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221738(US9314468, Table 7, Compound 25)
Affinity DataIC50:  10nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221873(US9314468, Table 8, Compound 11)
Affinity DataIC50:  11nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221800(US9314468, Table 7, Compound 87)
Affinity DataIC50:  11nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221761(US9314468, Table 7, Compound 48 | US9314468, Table...)
Affinity DataIC50:  12nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221876(US9314468, Table 8, Compound 14 | US9314468, Table...)
Affinity DataIC50:  12nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221875(US9314468, Table 8, Compound 13)
Affinity DataIC50:  12nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221874(US9314468, Table 8, Compound 12 | US9314468, Table...)
Affinity DataIC50:  12nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221832(US9314468, Table 7, Compound 119)
Affinity DataIC50:  13nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221858(US9314468, Table 7, Compound 145)
Affinity DataIC50:  14nMT: 2°CAssay Description:Functional modulation of CXCR4 was determined by calcium mobilization assay using leukemic lymphoid CEM cells, which naturally express high levels of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetC-X-C chemokine receptor type 4(Homo sapiens (Human))
Altiris Therapeutics

US Patent
LigandPNGBDBM221877(US9314468, Table 8, Compound 15)
Affinity DataIC50:  15nMAssay Description:This assay measures the change in impedance that occurs when cells are stimulated with SDF-1a. Changes in shape and cytoskeleton result in a change o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 195 total ) | Next | Last >>
Jump to: